Boehringer Ingelheim’s late-stage data for lung disease candidate underwhelm some analysts

Boehringer Ingelheim claimed two Phase 3 wins for its PDE4 inhibitor in fibrotic lung diseases, but some Wall Street analysts said the candidate’s “modest” efficacy and limited combination potential could hamper its real-world use in ...